Navigation Links
PDL-1 antibody could help immune system fight off influenza viral infection, study suggests
Date:12/23/2013

An antibody that blocks a component of a key signaling pathway in the respiratory airways could help the immune system rid the body of the influenza virus, a new study suggests. The findings, from a team at The Research Institute at Nationwide Children's Hospital, not only offer a new approach to treating the flu, but also add new information about how the immune system responds to respiratory viral infections.

In this new work, published in the December issue of the Journal of Virology and highlighted in the journal Spotlight section, researchers examined the role a protein called programmed cell death receptor (PD-1) plays in the immune response to influenza virus. PD-1 is known to inhibit the function of T cells, the immune system's first line of defense against intracellular pathogens. While scientists have looked intently at PD-1 activity in chronic viral infections such as hepatitis and HIV, its involvement in acute infections was thought by many to be minor.

Emilio Flao, PhD, principal investigator in the Center for Vaccines and Immunity, disagreed. Several small studies in his lab had raised the possibility that PD-1 and its associated ligand PDL-1 were actually very important to the immune response to acute infection.

The researchers' earlier studies had shown that when PD-1 protein was expressed, but its ligand PDL-1 was not, the protein couldn't bind to T cells to inhibit the immune response. So, for this study, the scientists treated mice infected with influenza virus with an antibody that blocks the activity of PDL-1. Viral levels began to drop within three days of treatment with the PDL-1 antibody, which was administered intranasally. At day five, the viral levels were undetectable.

"The PDL-1 blockade is not directly acting on the virus," Dr. Flao says. "It is acting on the T cells, improving their function so that the immune system can fight the virus."

When they examined the PD-1/PDL-1 response to influenza virus infection in human cell cultures, the scientists discovered that the activity of the protein and its ligand mimicked what they had seen in their mouse models. The findings from this study, coupled with the human tissue observations in the lab, suggest that an aerosolized version of the antibody, administered intranasally, could help the body clear the influenza virus.

"Sometimes it's better to enhance our own defenses and improve how they work rather than trying to target the virus," Dr. Flao says.

Scientists have eyed a PD-1/PDL-1 blockade as a way to treat hepatitis, HIV and other persistent viral infections, but their efforts have so far yielded mixed results in humans. Using the blockade to boost immune response against influenza is a simpler task because the infection is localized to the airways, Dr. Flao hypothesizes.

Dr. Flao and colleagues were also interested in how epithelial cells in the airwaysthe main targets of the influenza virusrespond to the attack and how their reaction might influence the immune system over the course of an infection.

"The original view has been that epithelial cells aren't all that important, but we are trying to change that, says Dr. Flao, who also is an associate professor of pediatrics at The Ohio State University College of Medicine. "The epithelial cells help orchestrate all the subsequent immune response in the body, and I truly believe that what they do at the onset of infection will determine what happens one week or 10 days later, when the immune system is responding at full speed."


'/>"/>

Contact: Mary Ellen Peacock
maryellen.peacock@nationwidechildrens.org
614-355-0495
Nationwide Children's Hospital
Source:Eurekalert

Related medicine news :

1. Antibody therapy prevents gastrointestinal damage following radiation exposure in mice
2. Scientists Pinpoint Antibody That May Be Specific to MS Patients
3. NIH scientists map first steps in flu antibody development
4. Elevated Antibody Levels May Predict Rheumatoid Arthritis Risk
5. New monoclonal antibody inhibits tumor growth in advanced solid tumors in phase I clinical trial
6. Antibody-coated stents: Indication of disadvantages
7. Evolution in the antibody factory
8. Scientists ID Antibody That Might Boost Cancer Therapy
9. Your Autoantibody Profile Might Someday Help Spot Illness
10. Monoclonal antibody appears effective and safe in asthma Phase IIa trial
11. Healthcare Antibody Market Partnering Deals And Agreements Analysis in New Research Report at ReportsnReports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... ... 2017 , ... HMP , a leader in healthcare events and education, today ... Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & ... award competition recognizes editorial and design excellence across a range of sectors. This year’s ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & Wellness ... Moonlight to raise money for the American Heart Association Heart Walk. Teams of up ... work together to keep their treadmills moving for 5 hours. Treadmills will start at ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), creator ... tool, and the Cancer Patient Education Network (CPEN), an independent professional organization that ... new strategic alliance. , As CPEN’s strategic partner, HLI will help support ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical ... to physician colleagues, skilled nursing facility medical directors and other clinicians at various ... Wound Care." , "At many of these conferences we get to educate other ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Divoti USA will engrave and process all non-coated ... latest FDA requirements, which stipulates new criteria regarding medical device manufacture ... Medical ID jewelry such as Medical ID Bracelets, can rest assured ... of the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving process ...
(Date:10/11/2017)... -- Caris Life Sciences ® , a leading innovator in ... medicine, today announced that St. Jude Medical Center,s Crosson ... as its 17 th member. Through participation with ... Institute will help develop standards of care and best ... cancer treatment more precise and effective. ...
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance ... a medical-grade battery-powered display stand specifically designed for endoscopy environments. An ... technology into a clinical solution to support the improvement of patient ... Innovative Design ... Wireless Solution ...
Breaking Medicine Technology: